| Microbiota-derived metabolites in tumor progression and metastasis T Rossi, D Vergara, F Fanini, M Maffia, S Bravaccini, F Pirini International Journal of Molecular Sciences 21 (16), 5786, 2020 | 114 | 2020 |
| Single-cell NGS-based analysis of copy number alterations reveals new insights in circulating tumor cells persistence in early-stage breast cancer T Rossi, G Gallerani, D Angeli, C Cocchi, E Bandini, P Fici, M Gaudio, ... Cancers 12 (9), 2490, 2020 | 34 | 2020 |
| Immunosuppressive Treg cells acquire the phenotype of effector-T cells in chronic lymphocytic leukemia patients S De Matteis, C Molinari, G Abbati, T Rossi, R Napolitano, M Ghetti, ... Journal of translational medicine 16, 1-9, 2018 | 34 | 2018 |
| Adipocytes and microRNAs crosstalk: a key tile in the mosaic of breast cancer microenvironment E Bandini, T Rossi, G Gallerani, F Fabbri Cancers 11 (10), 1451, 2019 | 23 | 2019 |
| E-cadherin downregulation and microRNAs in sporadic intestinal-type gastric cancer T Rossi, G Tedaldi, E Petracci, R Abou Khouzam, GN Ranzani, ... International Journal of Molecular Sciences 20 (18), 4452, 2019 | 22 | 2019 |
| miR-9-5p as a regulator of the androgen receptor pathway in breast cancer cell lines E Bandini, F Fanini, I Vannini, T Rossi, M Plousiou, MM Tumedei, ... Frontiers in Cell and Developmental Biology 8, 579160, 2020 | 17 | 2020 |
| Circulating tumour cells: detection and application in advanced non-small cell lung cancer K Andrikou, T Rossi, A Verlicchi, I Priano, P Cravero, MA Burgio, L Crinò, ... International Journal of Molecular Sciences 24 (22), 16085, 2023 | 12 | 2023 |
| Dissecting molecular heterogeneity of circulating tumor cells (CTCs) from metastatic breast cancer patients through copy number aberration (CNA) and single nucleotide variant … T Rossi, D Angeli, M Tebaldi, P Fici, E Rossi, A Rocca, M Palleschi, ... Cancers 14 (16), 3925, 2022 | 10 | 2022 |
| Early detection and investigation of extracellular vesicles biomarkers in breast cancer E Bandini, T Rossi, E Scarpi, G Gallerani, I Vannini, S Salvi, I Azzali, ... Frontiers in Molecular Biosciences 8, 732900, 2021 | 9 | 2021 |
| Circulating tumor cells as a tool to untangle the breast cancer heterogeneity issue T Rossi, G Gallerani, G Martinelli, R Maltoni, F Fabbri Biomedicines 9 (9), 1242, 2021 | 9 | 2021 |
| Obesity and dose of anti-cancer therapy: are we sure to be on the right track in the precision medicine era? T Rossi, E Bandini, W Balzi, F Fabbri, I Massa, R Maltoni Frontiers in Medicine 8, 725346, 2021 | 7 | 2021 |
| Extracellular Vesicles, Circulating Tumor Cells, and Immune Checkpoint Inhibitors: Hints and Promises S Bandini, P Ulivi, T Rossi Cells 13 (4), 337, 2024 | 5 | 2024 |
| Analysis of EVs from patients with advanced pancreatic cancer identifies antigens and miRNAs with predictive value I Vannini, T Rossi, M Melloni, M Valgiusti, M Urbini, A Passardi, G Bartolini, ... Molecular Therapy Methods & Clinical Development 29, 473-482, 2023 | 5 | 2023 |
| Appropriateness and Economic Analysis of Conventional Circulating Biomarkers Assessment in Early Breast Cancer: A Real-World Experience from the E. Pic. A Study R Maltoni, W Balzi, T Rossi, F Fabbri, S Bravaccini, MT Montella, I Massa, ... Current Oncology 29 (2), 433-438, 2022 | 4 | 2022 |
| Case report: Analysis of circulating tumor cells in a triple negative spindle-cell metaplastic breast cancer patient T Rossi, M Palleschi, D Angeli, M Tebaldi, G Martinelli, I Vannini, ... Frontiers in Medicine 8, 689895, 2021 | 4 | 2021 |
| Settling the uncertainty about unconventional circulating tumor cells: Epithelial-to-mesenchymal transition, cell fusion and trogocytosis G Gallerani, T Rossi, M Ferracin, M Bonafè International Review of Cell and Molecular Biology 381, 99-111, 2023 | 2 | 2023 |
| From phenotypical investigation to RNA-sequencing for gene expression analysis: A workflow for single and pooled rare cells T Rossi, D Angeli, G Martinelli, F Fabbri, G Gallerani Frontiers in Genetics 13, 1012191, 2022 | 2 | 2022 |
| CNA Profiling of Single CTCs in Locally Advanced Esophageal Cancer Patients during Therapy Highlights Unexplored Molecular Pathways G Gallerani, T Rossi, M Valgiusti, D Angeli, P Fici, S De Fanti, E Bandini, ... Cancers 13 (24), 6369, 2021 | 2 | 2021 |
| Synergic activity of FGFR2 and MEK inhibitors in the treatment of FGFR2-amplified cancers of unknown primary A Cavazzoni, I Salamon, C Fumarola, G Gallerani, N Laprovitera, ... Molecular Therapy 32 (10), 3650-3668, 2024 | 1 | 2024 |
| A Novel FLCN Variant in a Suspected Birt–Hogg–Dubè Syndrome Patient E Bandini, V Zampiga, I Cangini, M Ravegnani, V Arcangeli, T Rossi, ... International Journal of Molecular Sciences 24 (15), 12418, 2023 | 1 | 2023 |
